UnitedHealth Group (NYSE:UNH) Announces Quarterly Earnings Results

UnitedHealth Group (NYSE:UNH) announced its earnings results on Thursday. The healthcare conglomerate reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.46 by $0.14, RTT News reports. UnitedHealth Group had a return on equity of 25.20% and a net margin of 5.51%. The business had revenue of $60.60 billion for the quarter, compared to analysts’ expectations of $60.59 billion. During the same quarter last year, the firm earned $3.14 EPS. The business’s revenue for the quarter was up 8.0% on a year-over-year basis. UnitedHealth Group updated its FY 2019 guidance to $14.70-14.90 EPS and its FY19 guidance to $14.70-14.90 EPS.

Shares of UNH stock opened at $256.65 on Friday. The stock has a market cap of $243.91 billion, a price-to-earnings ratio of 18.31, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.67 and a quick ratio of 0.73. The stock has a fifty day moving average price of $249.00. UnitedHealth Group has a 1 year low of $208.07 and a 1 year high of $287.94.

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 25th. Investors of record on Monday, June 17th were paid a $1.08 dividend. This is a positive change from UnitedHealth Group’s previous quarterly dividend of $0.90. The ex-dividend date was Friday, June 14th. This represents a $4.32 dividend on an annualized basis and a yield of 1.68%. UnitedHealth Group’s dividend payout ratio (DPR) is 33.54%.



Several brokerages have recently commented on UNH. UBS Group set a $36.00 price objective on Halliburton and gave the company a “buy” rating in a report on Tuesday, April 23rd. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Tuesday, July 16th. Raymond James reiterated an “average” rating on shares of Grupo Aeroportuario dl Srst SAB CV in a report on Friday. Bank of America reiterated a “buy” rating and set a C$10.00 price objective on shares of Hexo in a report on Wednesday, April 17th. Finally, ValuEngine lowered Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $296.56.

In related news, Director Richard T. Burke sold 10,000 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $229.75, for a total value of $2,297,500.00. Following the completion of the transaction, the director now owns 187,663 shares in the company, valued at approximately $43,115,574.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William C. Ballard, Jr. sold 5,000 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $239.02, for a total value of $1,195,100.00. Following the completion of the transaction, the director now owns 77,993 shares of the company’s stock, valued at approximately $18,641,886.86. The disclosure for this sale can be found here. Insiders sold a total of 35,000 shares of company stock valued at $8,392,500 in the last 90 days. 0.87% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the stock. Gantzert Investment Co. LLC ADV bought a new position in UnitedHealth Group in the fourth quarter valued at about $1,847,000. Buckingham Capital Management Inc. grew its position in UnitedHealth Group by 2.4% in the fourth quarter. Buckingham Capital Management Inc. now owns 24,287 shares of the healthcare conglomerate’s stock valued at $6,050,000 after acquiring an additional 558 shares during the last quarter. Greenleaf Trust grew its position in UnitedHealth Group by 14.1% in the fourth quarter. Greenleaf Trust now owns 13,789 shares of the healthcare conglomerate’s stock valued at $3,435,000 after acquiring an additional 1,704 shares during the last quarter. Athena Capital Advisors LLC bought a new position in UnitedHealth Group in the fourth quarter valued at about $226,000. Finally, First Trust Advisors LP grew its position in UnitedHealth Group by 24.2% in the fourth quarter. First Trust Advisors LP now owns 381,606 shares of the healthcare conglomerate’s stock valued at $95,066,000 after acquiring an additional 74,462 shares during the last quarter. Institutional investors own 85.62% of the company’s stock.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Read More: Asset Allocation Models, Which is Right For You?

Earnings History for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.